Ribonova Inc. – Trademark Portfolio

Entity Type: 03

Ribonova Inc. holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 1 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include RIBONOVA. The owner is based in Wynnewood, PA.

Lankenau Inst for Medical Research R133

100 East Lancaster Avenue

Wynnewood, PA 19096

2 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

RIBONOVA
RIBONOVA
Registered 2011
RIBONOVA
RIBONOVA
Registered 2011

Trademark Classifications

Ribonova Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

42
Computer & Scientific (1 filing)

Scientific and technological services; industrial analysis and research services

5
Pharmaceuticals (1 filing)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does Ribonova Inc. have?

Ribonova Inc. has 2 U.S. trademarks filed with the USPTO. Of these, 2 registered.

What trademark classes does Ribonova Inc. file in?

Ribonova Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 5 (Pharmaceuticals). Class 42 covers scientific and technological services; industrial analysis and research services.

What are Ribonova Inc.'s most well-known trademarks?

Ribonova Inc.'s registered trademark portfolio includes well-known marks such as RIBONOVA. These are among 2 currently registered trademarks in the portfolio.

What is Ribonova Inc.'s trademark registration success rate?

Ribonova Inc. has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.